*Doses are commonly-reported figures from public sources, not a recommendation. Educational only.
| Year | Title / venue | Source |
|---|---|---|
| 2024 | Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder Journal of sex research · preclinical | PMID 36809187 |
| 2023 | Targeting the central melanocortin system for the treatment of metabolic disorders Nature reviews. Endocrinology · preclinical | PMID 37365323 |
| 2023 | An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder Expert opinion on pharmacotherapy · preclinical | PMID 36242769 |
| 2022 | Medical Treatment of Female Sexual Dysfunction The Urologic clinics of North America · preclinical | PMID 35428435 |
| 2022 | Bremelanotide for Treatment of Female Hypoactive Sexual Desire Neurology international · preclinical | PMID 35076581 |
| 2022 | Safety Profile of Bremelanotide Across the Clinical Development Program Journal of women's health (2002) · human | PMID 35147466 |
| 2021 | Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment Journal of midwifery & women's health · preclinical | PMID 34510696 |
| 2021 | Re-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women Journal of sex research · preclinical | PMID 33678061 |
| 2020 | Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder The Annals of pharmacotherapy · preclinical | PMID 31893927 |
| 2019 | Bremelanotide: First Approval Drugs · preclinical | PMID 31429064 |
| 2019 | Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials Obstetrics and gynecology · human | PMID 31599840 |
| 2012 | Bremelanotide · preclinical | PMID 34436837 |
| 2006 | Bremelanotide · preclinical | PMID 31369224 |
| 2006 | An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist The journal of sexual medicine · human | PMID 16839319 |
| 2004 | PT-141 Palatin Current opinion in investigational drugs (London, England : 2000) · preclinical | PMID 15134289 |
PT-141 (Bremelanotide (PT-141)). Synthetic cyclic melanocortin receptor agonist (primarily MC4R), a metabolite of Melanotan II. Acts centrally in the hypothalamus to influence sexual arousal pathways independent of the vascular mechanism of PDE5 inhibitors.
Commonly discussed uses: hypoactive sexual desire disorder (approved indication, premenopausal women), libido (off-label/anecdotal). There is both human and animal/preclinical research, though the depth and quality vary by indication. Note: most uses are not approved indications.
Mechanism: Synthetic cyclic melanocortin receptor agonist (primarily MC4R), a metabolite of Melanotan II. Acts centrally in the hypothalamus to influence sexual arousal pathways independent of the vascular mechanism of PDE5 inhibitors.
Reported considerations: nausea (common), flushing, headache, transient blood-pressure increase, focal hyperpigmentation with repeated use. There is both human and animal/preclinical research, though the depth and quality vary by indication. FDA-approved as Vyleesi for a specific indication. Grey-market PT-141 is not the approved product. This is not a safety endorsement; safety data for unapproved compounds is incomplete.
Commonly cited ranges (educational reference, not a recommendation): low 0.5-1mg, typical 1.75mg SC (approved dose), high 2mg (off-label, higher side-effect risk). Administration: subcutaneous. Half-life: ~2.7 hours.
Australian status: Not ARTG-registered (Vyleesi not marketed in AU); prescription-only if compounded. FDA-approved as Vyleesi for a specific indication. Grey-market PT-141 is not the approved product. General regulatory context: most active peptides are Schedule 4 and require a prescription; import via the Personal Importation Scheme requires a valid Australian prescription for prescription-only goods.
Reconstitution/storage reference: approved product pre-filled autoinjector; research vials vary; storage: refrigerated.
Commonly discussed combinations (anecdotal for unapproved compounds): used standalone; not for stacking. Stacking increases interaction/safety uncertainty.